Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7.7 million contracted units added in under two weeks — Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today
Secured orders for 1.04 million units annually — 5.2 million over five years — under new agreements with Target Pharma
Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026
Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows
Division targeted to generate over $10 million in recurring annual profit at full capacity
CHICAGO, IL / ACCESS Newswire / September 15, 2026 / Cosmos Health Inc. (NASDAQ: COSM) ("Cosmos Health" or the "Company"), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2 million units.
| Metric | Current Position |
|---|---|
| Orderbook | 32.7M+ units |
| Growth Since June | +31% in under three months |
| Added in September | 7.7M units across two agreements |
| Agreement Terms | Up to 10 years |
The agreements secure orders for approximately 1.04 million units annually and lift Cana's cumulative orderbook to more than 32.7 million units — a 31% increase since June 2026, achieved through two agreements signed in under two weeks.
Target Pharma Agreements: 5.2 Million Units Across Dermatology and Anti-Infectives
| Product | Annual Units | Five-Year Total | Category |
|---|---|---|---|
| MUPIROCIN | ~900,000 | ~4.5 million | Topical antibiotic (dermatology) |
| TRETIN | ~140,000 | ~700,000 | Retinoid (acne treatment) |
| Total | ~1.04 million | ~5.2 million |
MUPIROCIN is a topical ointment marketed by Target Pharma as a 20 mg/g (2%) formulation in 15 g and 30 g tubes. Its active ingredient, mupirocin, is a topical antibiotic that inhibits bacterial isoleucyl-tRNA synthetase, disrupting bacterial protein synthesis.
TRETIN is based on isotretinoin, a retinoid derivative of vitamin A used in the treatment of acne, and forms part of Target Pharma's dermatology portfolio.
Building Momentum
September has been an active month for new contracted volume at Cana. The Target Pharma agreements follow the five-year ROSARTIA agreement with Viofar announced on September 11, taking total units added this month to 7.7 million and extending Cana's coverage to 11 therapeutic categories, up from nine in June 2026, with the addition of cardiovascular and anti-infective.
That breadth reduces dependence on any single product, partner or category, and the Company expects it to support a more stable base of recurring production across agreements extending up to ten years.
Converting Infrastructure into Contracted Production
Cana operates Cosmos Health's wholly owned 54,000-square-foot facility in Athens, licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA).
The Company has invested approximately $5.5 million upgrading the site, including manufacturing equipment, IT infrastructure, quality management systems and a new ACG capsule-filling line.
That investment is now being converted into contracted, recurring production. Cana's orderbook has grown from over 12 million units earlier this year to more than 32.7 million units today.
As previously disclosed, the division is targeted to generate over $10 million in recurring annual profit at full capacity.
Orderbook Growth at a Glance
| Milestone | Contracted Units |
|---|---|
| Earlier in 2026 | 12M+ |
| June 2026 | ~25M |
| September 11 — Viofar Agreement | +2.5M |
| September 15 — Target Pharma Agreements | +5.2M |
| Current Orderbook | 32.7M+ |
| Growth Since June | +31% |
| Added in September | 7.7M |
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated:
"We have added 7.7 million contracted units this month alone and grown the orderbook 31% since June, and close to threefold since the start of the year. That is not incremental progress — it is a significant step change in the scale of this division.
"Established pharmaceutical companies are choosing Cana because we built a facility that meets their standards and we deliver. Every agreement we sign turns infrastructure we have already paid for into long-term, contracted production at attractive margins. We are not finished — the pipeline of opportunities in front of us is the strongest it has been."
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group.
The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.
Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices within the European Union.
Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK.
Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics and innovative OTC products.
Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA.
With a global distribution platform, the Company is currently expanding throughout Europe, Asia and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.
More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co and www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words.
These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to:
- The Company's ability to raise sufficient financing to implement its business plan
- The effectiveness of its digital asset strategies, including accumulation and yield-generating activities
- The impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations and the economy in general
- The Company's ability to successfully develop and commercialize its proprietary products and technologies
- Changes in interest rates
- Changes in foreign currency exchange rates, commodity prices or other price inflation and deflation
- The Company's ability to issue debt on terms and at rates acceptable to it
- The impact and expected outcome of investigations, inquiries, claims and litigation
- The challenges of operating in international markets
- The adequacy of insurance coverage
- The effect of accounting charges and the adoption of certain accounting standards
- The impact of legal and regulatory changes, including changes to tax laws and regulations
- Guidance for fiscal 2026 and beyond and the Company's financial outlook
Forward-looking statements are based on currently available information and the Company's current assumptions, expectations and projections about future events.
Readers should not rely on forward-looking statements as guarantees of future performance.
These statements are subject to future events, risks and uncertainties, many of which are beyond the Company's control, dependent on the actions of third parties or currently unknown, as well as potentially inaccurate assumptions that could cause actual results to differ materially from historical experience, expectations and projections.
These risks and uncertainties include, but are not limited to, those described from time to time in the Company's periodic reports filed with the U.S. Securities and Exchange Commission (SEC) and available through the SEC's website at www.sec.gov.
There also may be other factors the Company cannot anticipate or that are not described herein, generally because it does not currently perceive them to be material. Such factors could cause results to differ materially from expectations.
Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements other than as required by law.
Readers are advised to review any further disclosures the Company makes on related subjects in its filings with the Securities and Exchange Commission and in its other public statements.
Investor Relations Contact
BDG Communications
Email: cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.